None of the participants had a previous heart attack. Mean follow-up was five years. By significantly decreasing the incidence of heart attack, therefore, it is anticipated that pravastatin therapy in this population will have a favorable impact on healthcare expenditures. A cost-effectiveness analysis based on the WOS study is currently being developed. CARE is scheduled for completion in February 1996.
Pravastatin is generally well tolerated.
The most common side effects include mild and transient skin rash and gastrointestinal upset, and are similar to those seen with placebo. The WOS study was conducted by the University of Glasgow, Scotland, and funded by a grant from Bristol-Myers Squibb . It was conducted in and around the city of Glasgow, where the local population utilizes a highly centralized primary-care service and few people move in and out of the community, making it feasible to monitor participants over time. Consulting Group Inc. All rights reserved. Please contact us with any comments, problems or bugs.